{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:08:48Z","timestamp":1790723328643,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["EQU201903007846"],"award-info":[{"award-number":["EQU201903007846"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-21-CE14-0051"],"award-info":[{"award-number":["ANR-21-CE14-0051"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health funds","award":["GR-2019-12370560"],"award-info":[{"award-number":["GR-2019-12370560"]}]},{"name":"Italian Ministry of Health funds","award":["GR-2018-12366423"],"award-info":[{"award-number":["GR-2018-12366423"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) is a key regulator of plasma low-density lipoprotein cholesterol (LDL-C) concentration, and its inhibition reduces the risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to assess the sex-differential effect of either pharmacological or genetic inhibition of PCSK9 on LDL-C levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We meta-analyzed six real-life studies (1216 men and 641 women) that investigated the effects of PCSK9 monoclonal antibodies (mAbs) on LDL-C reduction in men and women. Despite higher LDL-C levels in women at baseline [mean difference (MD)\u00a0=\u00a017.4\u00a0mg\/dL, P\u00a0&amp;lt;\u00a00.0001, women = 175\u00a0mg\/dL vs. men = 152\u00a0mg\/dL], the LDL-C reduction under PCSK9 mAb treatment was significantly greater in men (MD\u00a0=\u00a07.6\u00a0mg\/dL, 95% confidence interval: 2.7\u201312.4, P\u00a0=\u00a00.002) than in women.<\/jats:p>\n                    <jats:p>We tested the sex-related association of the loss-of-function variant PCSK9-R46L with LDL-C plasma levels in 382\u2009813 individuals (219\u2009301 women and 163\u2009512 men) free of lipid-lowering drugs from the UK Biobank general population cohort. The magnitude of LDL-C reduction was larger in men than in women (mean LDL-C difference: \u201335\u00a0mg\/dL vs. \u201326\u00a0mg\/dL, when comparing homozygous carriers with non-carriers in men and women, respectively). The relationship between PCSK9-R46L and LDL-C was significantly dependent on sex (P for interaction\u00a0=\u00a07.2e\u201304).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results demonstrate by complementary approaches that the decrease in LDL-C mediated by PCSK9 inhibition is slightly, but significantly, less marked in women than in men. These data reinforce the need for specific studies to develop sex-specific recommendations for the management of ASCVD in women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad009","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T13:33:46Z","timestamp":1675258426000},"page":"337-342","source":"Crossref","is-referenced-by-count":28,"title":["LDL lowering effect of PCSK9 inhibition is reduced in women"],"prefix":"10.1093","volume":"9","author":[{"given":"Veronika A","family":"Myasoedova","sequence":"first","affiliation":[{"name":"Centro Cardiologico Monzino IRCCS , Via Carlo Parea 4, 20138, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-4926","authenticated-orcid":false,"given":"Antoine","family":"Rimbert","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, CNRS, INSERM, l'institut du thorax , F- 44000 Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Camera","sequence":"additional","affiliation":[{"name":"Centro Cardiologico Monzino IRCCS , Via Carlo Parea 4, 20138, Milan , Italy"},{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Milano , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Le May","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, CNRS, INSERM, l'institut du thorax , F- 44000 Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-7409","authenticated-orcid":false,"given":"Romain","family":"Capoulade","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, CNRS, INSERM, l'institut du thorax , F- 44000 Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-8040","authenticated-orcid":false,"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, CNRS, INSERM, l'institut du thorax , F- 44000 Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7225-3379","authenticated-orcid":false,"given":"Paolo","family":"Poggio","sequence":"additional","affiliation":[{"name":"Centro Cardiologico Monzino IRCCS , Via Carlo Parea 4, 20138, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"2023060210540545900_bib1","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"2023060210540545900_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","article-title":"Inhibiting PCSK9\u2014biology beyond LDL control","volume":"15","author":"Stoekenbroek","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2023060210540545900_bib3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","article-title":"Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population","volume":"213","author":"Cui","year":"2010","journal-title":"Atherosclerosis"},{"key":"2023060210540545900_bib4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2023060210540545900_bib5","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1210\/en.2008-1281","article-title":"Importance of proprotein convertase subtilisin\/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors","volume":"150","author":"Persson","year":"2009","journal-title":"Endocrinology"},{"key":"2023060210540545900_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.111.242461","article-title":"Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women","volume":"32","author":"Persson","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023060210540545900_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","article-title":"Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study","volume":"309","author":"Ferri","year":"2020","journal-title":"Atherosclerosis"},{"key":"2023060210540545900_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40200-020-00557-6","article-title":"Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials","volume":"19","author":"Cordero","year":"2020","journal-title":"J Diabetes Metab Disord"},{"key":"2023060210540545900_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamacardio.2022.2333","article-title":"Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial mendelian randomization study","volume":"7","author":"Cupido","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2023060210540545900_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/2047487320902750","article-title":"LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial","volume":"28","author":"Sever","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2023060210540545900_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FJC.0000000000001205","article-title":"Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: the LIPID-REAL registry","volume":"79","author":"Cordero","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2023060210540545900_bib12","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2023060210540545900_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2023060210540545900_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"2023060210540545900_bib15","doi-asserted-by":"crossref","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"2023060210540545900_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: rising to the challenge of larger and richer datasets","volume":"4","author":"Chang","year":"2015","journal-title":"Gigascience"},{"key":"2023060210540545900_bib17","doi-asserted-by":"crossref","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek","year":"2021","journal-title":"Gigascience"},{"key":"2023060210540545900_bib18","first-page":"189","author":"Wickham","year":"2016","journal-title":"ggplot2 Data Analysis. Elegant Graphics for Data Analysis."},{"key":"2023060210540545900_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.atherosclerosis.2022.06.672","article-title":"Sex differences in efficacy and side effects of proprotein convertase subtilisin \/kexin 9 (PCSK9) inhibitors in real world data","volume":"355","author":"Galema-Boers","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023060210540545900_bib20","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.numecd.2020.06.028","article-title":"Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: a retrospective, single center, observational study","volume":"30","author":"D'erasmo","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2023060210540545900_bib21","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/03007995.2020.1786678","article-title":"Efficacy and tolerability of alirocumab in Austrian clinical practice\u2014results of the non-interventional PEARL-AT study","volume":"36","author":"Leitner","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2023060210540545900_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40801-019-0158-0","article-title":"PEARL: a non-interventional study of real-world alirocumab use in German clinical practice","volume":"6","author":"Parhofer","year":"2019","journal-title":"Drugs Real World Outcomes"},{"key":"2023060210540545900_bib23","doi-asserted-by":"crossref","first-page":"112519","DOI":"10.1016\/j.biopha.2021.112519","article-title":"PCSK9 inhibitors revisited: effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort","volume":"146","author":"Vicente-Valor","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2023060210540545900_bib24","doi-asserted-by":"crossref","first-page":"159217","DOI":"10.1016\/j.bbalip.2022.159217","article-title":"PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: role of hepatic cholesterol","author":"Roubtsova","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2023060210540545900_bib25","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1194\/jlr.M061952","article-title":"PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice","volume":"56","author":"Roubtsova","year":"2015","journal-title":"J Lipid Res"},{"key":"2023060210540545900_bib26","doi-asserted-by":"crossref","first-page":"e009221","DOI":"10.1161\/JAHA.118.009221","article-title":"Lower on-treatment low-density lipoprotein cholesterol and major adverse cardiovascular events in women and men: pooled analysis of 10 ODYSSEY phase 3 alirocumab trials","volume":"7","author":"Vallejo-Vaz","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2023060210540545900_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2023060210540545900_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2017.10.006","article-title":"Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry","volume":"267","author":"Amrock","year":"2017","journal-title":"Atherosclerosis"},{"key":"2023060210540545900_bib29","doi-asserted-by":"crossref","first-page":"104514","DOI":"10.1016\/j.phrs.2019.104514","article-title":"Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: need for customisation strategies","volume":"155","author":"Olmastroni","year":"2020","journal-title":"Pharmacol Res"},{"key":"2023060210540545900_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5114\/aoms\/143476","article-title":"Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"key":"2023060210540545900_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pcad.2020.03.012","article-title":"Non-statin interventions in the prevention of cardiovascular events: sex-based meta-analysis","volume":"63","author":"Das","year":"2020","journal-title":"Prog Cardiovasc Dis"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad009\/49005539\/pvad009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/4\/337\/50508267\/pvad009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/4\/337\/50508267\/pvad009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T17:30:25Z","timestamp":1685727025000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/4\/337\/7017832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2,20]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad009","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,2,20]]}}}